Immune checkpoint therapies targeting CTLA-4 and PD-1/PD-L1 are the main drugs used in the treatment of HCC, and other immunotherapies are rapidly evolving, including CAR-T cells, TCR-T cells, therapeutic vaccines, and OVs. Here, PDCD1 is linked to hepatocellular carcinoma.